Acute exacerbation of idiopathic pulmonary fibrosis-A review of current and novel pharmacotherapies

Maya M. Juarez, Andrew Chan, Andrew G. Norris, Brian M Morrissey, Timothy E Albertson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive form of lung disease of unknown etiology for which a paucity of therapies suggest benefit, and for which none have demonstrated improved survival. Acute exacerbation of IPF (AE-IPF) is defined as a sudden acceleration of the disease or an idiopathic acute injury superimposed on diseased lung that leads to a significant decline in lung function. An AE-IPF is associated with a mortality rate as high as 85% with mean survival periods of between 3 to 13 days. Under these circumstances, mechanical ventilation (MV) is controversial, unless used a as a bridge to lung transplantation. Judicious fluid management may be helpful. Pharmaceutical treatment regimens for AE-IPF include the use of high dose corticosteroids with or without immunosuppressive agents such as cyclosporine A (CsA), and broad spectrum antibiotics, despite the lack of convincing evidence demonstrating benefit. Newer research focuses on abnormal wound healing as a cause of fibrosis and preventing fibrosis itself through blocking growth factors and their downstream intra-cellular signaling pathways. Several novel pharmaceutical approaches are discussed.

Original languageEnglish (US)
Pages (from-to)499-519
Number of pages21
JournalJournal of Thoracic Disease
Volume7
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Lung Diseases
Fibrosis
Drug Therapy
Lung Transplantation
Immunosuppressive Agents
Artificial Respiration
Pharmaceutical Preparations
Wound Healing
Cyclosporine
Intercellular Signaling Peptides and Proteins
Adrenal Cortex Hormones
Anti-Bacterial Agents
Lung
Mortality
Wounds and Injuries
Therapeutics
Research
blocking factor

Keywords

  • Acute exacerbation (AE)
  • Clinical trials
  • Drug therapy
  • Idiopathic pulmonary fibrosis (IPF)
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Acute exacerbation of idiopathic pulmonary fibrosis-A review of current and novel pharmacotherapies. / Juarez, Maya M.; Chan, Andrew; Norris, Andrew G.; Morrissey, Brian M; Albertson, Timothy E.

In: Journal of Thoracic Disease, Vol. 7, No. 3, 2015, p. 499-519.

Research output: Contribution to journalArticle

@article{3872c3e7f8be4f8e933ddf5ecdc80f69,
title = "Acute exacerbation of idiopathic pulmonary fibrosis-A review of current and novel pharmacotherapies",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive form of lung disease of unknown etiology for which a paucity of therapies suggest benefit, and for which none have demonstrated improved survival. Acute exacerbation of IPF (AE-IPF) is defined as a sudden acceleration of the disease or an idiopathic acute injury superimposed on diseased lung that leads to a significant decline in lung function. An AE-IPF is associated with a mortality rate as high as 85{\%} with mean survival periods of between 3 to 13 days. Under these circumstances, mechanical ventilation (MV) is controversial, unless used a as a bridge to lung transplantation. Judicious fluid management may be helpful. Pharmaceutical treatment regimens for AE-IPF include the use of high dose corticosteroids with or without immunosuppressive agents such as cyclosporine A (CsA), and broad spectrum antibiotics, despite the lack of convincing evidence demonstrating benefit. Newer research focuses on abnormal wound healing as a cause of fibrosis and preventing fibrosis itself through blocking growth factors and their downstream intra-cellular signaling pathways. Several novel pharmaceutical approaches are discussed.",
keywords = "Acute exacerbation (AE), Clinical trials, Drug therapy, Idiopathic pulmonary fibrosis (IPF), Treatment",
author = "Juarez, {Maya M.} and Andrew Chan and Norris, {Andrew G.} and Morrissey, {Brian M} and Albertson, {Timothy E}",
year = "2015",
doi = "10.3978/j.issn.2072-1439.2015.01.17",
language = "English (US)",
volume = "7",
pages = "499--519",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

TY - JOUR

T1 - Acute exacerbation of idiopathic pulmonary fibrosis-A review of current and novel pharmacotherapies

AU - Juarez, Maya M.

AU - Chan, Andrew

AU - Norris, Andrew G.

AU - Morrissey, Brian M

AU - Albertson, Timothy E

PY - 2015

Y1 - 2015

N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive form of lung disease of unknown etiology for which a paucity of therapies suggest benefit, and for which none have demonstrated improved survival. Acute exacerbation of IPF (AE-IPF) is defined as a sudden acceleration of the disease or an idiopathic acute injury superimposed on diseased lung that leads to a significant decline in lung function. An AE-IPF is associated with a mortality rate as high as 85% with mean survival periods of between 3 to 13 days. Under these circumstances, mechanical ventilation (MV) is controversial, unless used a as a bridge to lung transplantation. Judicious fluid management may be helpful. Pharmaceutical treatment regimens for AE-IPF include the use of high dose corticosteroids with or without immunosuppressive agents such as cyclosporine A (CsA), and broad spectrum antibiotics, despite the lack of convincing evidence demonstrating benefit. Newer research focuses on abnormal wound healing as a cause of fibrosis and preventing fibrosis itself through blocking growth factors and their downstream intra-cellular signaling pathways. Several novel pharmaceutical approaches are discussed.

AB - Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive form of lung disease of unknown etiology for which a paucity of therapies suggest benefit, and for which none have demonstrated improved survival. Acute exacerbation of IPF (AE-IPF) is defined as a sudden acceleration of the disease or an idiopathic acute injury superimposed on diseased lung that leads to a significant decline in lung function. An AE-IPF is associated with a mortality rate as high as 85% with mean survival periods of between 3 to 13 days. Under these circumstances, mechanical ventilation (MV) is controversial, unless used a as a bridge to lung transplantation. Judicious fluid management may be helpful. Pharmaceutical treatment regimens for AE-IPF include the use of high dose corticosteroids with or without immunosuppressive agents such as cyclosporine A (CsA), and broad spectrum antibiotics, despite the lack of convincing evidence demonstrating benefit. Newer research focuses on abnormal wound healing as a cause of fibrosis and preventing fibrosis itself through blocking growth factors and their downstream intra-cellular signaling pathways. Several novel pharmaceutical approaches are discussed.

KW - Acute exacerbation (AE)

KW - Clinical trials

KW - Drug therapy

KW - Idiopathic pulmonary fibrosis (IPF)

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84928592971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928592971&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2072-1439.2015.01.17

DO - 10.3978/j.issn.2072-1439.2015.01.17

M3 - Article

VL - 7

SP - 499

EP - 519

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 3

ER -